Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs Adaptive Biotechnologies Corp (ADPT) Price & Performance

Abbott LaboratoriesTrade
Adaptive Biotechnologies CorpTrade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs Adaptive Biotechnologies Corp — how do they compare? Abbott Laboratories trades at $109.01 (market cap $187.95B), while Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B). The key difference: Abbott Laboratories is far larger — about 46.5× Adaptive Biotechnologies Corp's market cap, and Abbott Laboratories pays a 2.32% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.

ABTADPT
Market Cap
$187.95B$4.04B
Sector
HealthHealth
52-Week High
$136.62$25.45
52-Week Low
$82.57$12.30
Enterprise Value
$214.96B$4.10B
Dividend Yield
2.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.

Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.

Adaptive Biotechnologies Corp

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT